Altimmune’s (ALT) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Altimmune (NASDAQ:ALT) in a research note released on Thursday,Benzinga reports. The firm currently has a $12.00 target price on the stock.

A number of other brokerages have also issued reports on ALT. B. Riley restated a “buy” rating and issued a $20.00 price target on shares of Altimmune in a research note on Monday, August 12th. UBS Group initiated coverage on shares of Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price for the company. Finally, Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.00.

Altimmune Trading Down 10.0 %

Shares of ALT stock opened at $7.61 on Thursday. Altimmune has a twelve month low of $2.34 and a twelve month high of $14.84. The company has a market capitalization of $541.22 million, a PE ratio of -4.91 and a beta of 0.09. The firm has a fifty day simple moving average of $7.02 and a 200-day simple moving average of $6.91.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million during the quarter. During the same quarter in the prior year, the business earned ($0.39) earnings per share. Equities research analysts predict that Altimmune will post -0.54 EPS for the current year.

Insider Buying and Selling

In other news, Director David Drutz sold 16,011 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the transaction, the director now owns 41,958 shares in the company, valued at approximately $289,510.20. This represents a 27.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is owned by company insiders.

Institutional Trading of Altimmune

Large investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC acquired a new position in Altimmune during the 3rd quarter valued at about $31,000. CANADA LIFE ASSURANCE Co bought a new stake in Altimmune during the first quarter worth approximately $44,000. TFO Wealth Partners LLC acquired a new stake in Altimmune in the first quarter worth approximately $51,000. Horizon Wealth Management LLC bought a new position in Altimmune during the 2nd quarter valued at $66,000. Finally, PFG Investments LLC acquired a new position in shares of Altimmune during the 2nd quarter valued at $67,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.